Stanford V Falls Short Against ABVD In Large Hodgkin's Trial

A recent randomized phase III trial, an intergroup study coordinated by the Eastern Cooperative Oncology Group, looked at outcomes in advanced Hodgkin's lymphoma patients to see if there was a benefit in receiving the Stanford V regimen compared to the ABVD regimen with or without radiation therapy in locally extensive and advanced Hodgkin's lymphoma.

Results from this trial indicate that the Stanford V regimen provides no additional benefit when compared with ABVD in patients with advanced Hodgkin’s lymphoma.

Even though ABVD therapy remains the standard therapy in most Hodgkin's lymphoma patients, researchers are always looking to improve upon it, and this trial appears to be no exception to that effort. Ideally, doctors want to see less toxicity and higher efficacy.

A challenger to ABVD is the Stanford V regimen which was created to minimize both short- and long-term toxicity. Recent phase II studies indicated that Stanford V might be better than ABVD, thus a phase III trial was carried out.

794 patients with advanced stage HL were analyzed

399 received the Stanford V regimen
-- 95.2% were administered 12 weeks of treatment
-- 75% received radiotherapy

395 received ABVD
-- 88.6% received six to eight cycles (32 weeks)
-- 41% received radiotherapy

Toxicity results and risks of secondary cancers were found to be similar between both groups, although the Stanford V group experienced more grade 3 lymphopenia and grade 3 or 4 leukocytopenia, while rates of sensory neuropathy and motor neuropathy were also higher in the Stanford V group.

However, the big finding involved the 5-year Failure-Free Survival Rates (71%) and the Overall Survival Rate (88%), which were lower than what had been found in prior phase II studies. This led researchers to conclude that Stanford V was not significantly superior to ABVD.

Source: Hope For Lymphoma

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...